Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) Stock Price Faces Q3 Earnings Squeeze
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report is about pharma and health and China.
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- FXI iShares China Large-Cap ETF-5.1% 30d
iShares China Large-Cap ETF holds stocks listed in China, which this story is about (“beijing”).
- LLY Eli Lilly and+20.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+9.0% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+3.3% 18d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -2.61% | -2.65% | base | +0.46% | +0.32% | +0.30% | after close |
| XBI | -5.24% | -1.88% | base | -1.17% | -3.65% | -1.55% | after close |
| FXI | -1.16% | -0.67% | base | +1.31% | +1.56% | after close | after close |
| LLY | -7.22% | -6.69% | base | +3.17% | +2.79% | after close | after close |
| JNJ | -4.11% | -2.34% | base | -0.69% | -1.67% | after close | after close |
| PFE | +0.20% | -0.53% | base | +1.84% | +2.54% | after close | after close |
| MRK | -0.71% | -3.06% | base | +2.20% | +1.45% | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) Stock Price Faces Q3 Earnings Squeeze Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| FXI | that day | +1.31% | final price |
| FXI | the next day | +1.56% | final price |
| FXI | three days earlier | -0.67% | final price |
| FXI | five days earlier | -1.16% | final price |
| JNJ | that day | -0.69% | final price |
| JNJ | the next day | -1.67% | final price |
| JNJ | three days earlier | -2.34% | final price |
| JNJ | five days earlier | -4.11% | final price |
| LLY | that day | +3.17% | final price |
| LLY | the next day | +2.79% | final price |
| LLY | three days earlier | -6.69% | final price |
| LLY | five days earlier | -7.22% | final price |
| MRK | that day | +2.20% | final price |
| MRK | the next day | +1.45% | final price |
| MRK | three days earlier | -3.06% | final price |
| MRK | five days earlier | -0.71% | final price |
| PFE | that day | +1.84% | final price |
| PFE | the next day | +2.54% | final price |
| PFE | three days earlier | -0.53% | final price |
| PFE | five days earlier | +0.20% | final price |
| XBI | that day | -1.17% | final price |
| XBI | the next day | -3.65% | final price |
| XBI | two days later | -1.55% | still updating |
| XBI | three days earlier | -1.88% | final price |
| XBI | five days earlier | -5.24% | final price |
| XLV | that day | +0.46% | final price |
| XLV | the next day | +0.32% | final price |
| XLV | two days later | +0.30% | still updating |
| XLV | three days earlier | -2.65% | final price |
| XLV | five days earlier | -2.61% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 30 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 52 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 70 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 36 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 72 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100Price not final
“Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) Stock Price Faces Q3 Earnings Squeeze” scores 12 out of 100. The score uses 1 sources. The price is not final yet.